Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Infant Bacterial Therapeutics AB (publ)
IBT-BInfant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden. Address: Bryggargatan 10, Stockholm, Sweden, 111 21
Analytics
Objectif de Cours de WallStreet
3 303.56 SEKRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés IBT-B
Analyse des dividendes IBT-B
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes IBT-B
Valorisation des titres IBT-B
financières IBT-B
Résultats | 2019 | Dynamique |